David Aaron Lehman Sells 14,334 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) General Counsel David Lehman sold 14,334 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,394.84. Following the sale, the general counsel owned 361,827 shares of the company’s stock, valued at approximately $817,729.02. This represents a 3.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Stock Performance

Pulmonx stock traded down $0.02 during trading hours on Thursday, hitting $2.26. The company had a trading volume of 284,129 shares, compared to its average volume of 512,534. The firm has a 50-day moving average of $1.79 and a 200 day moving average of $1.56. The company has a debt-to-equity ratio of 0.95, a current ratio of 4.32 and a quick ratio of 3.52. The firm has a market cap of $97.07 million, a PE ratio of -1.95 and a beta of 0.34. Pulmonx Corporation has a one year low of $1.13 and a one year high of $2.89.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%.The company had revenue of $22.76 million during the quarter, compared to analysts’ expectations of $22.39 million. On average, sell-side analysts expect that Pulmonx Corporation will post -1.05 earnings per share for the current year.

Institutional Trading of Pulmonx

A number of institutional investors have recently modified their holdings of the stock. Stonepine Capital Management LLC bought a new position in shares of Pulmonx in the second quarter worth $1,060,067. Parkman Healthcare Partners LLC bought a new stake in Pulmonx during the second quarter worth about $841,000. ADAR1 Capital Management LLC bought a new stake in Pulmonx during the second quarter worth about $526,000. Deutsche Bank AG acquired a new stake in Pulmonx during the second quarter worth about $523,000. Finally, Primecap Management Co. CA acquired a new stake in Pulmonx during the second quarter worth about $5,996,000. 91.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LUNG has been the topic of a number of recent research reports. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings raised shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Pulmonx currently has an average rating of “Moderate Buy” and an average target price of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.